Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

PURPOSE: ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%–2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, will soon be given alongside induction chemotherapy for children with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucker, Elizabeth R., Jiménez, Irene, Chen, Lindi, Bellini, Angela, Gorrini, Chiara, Calton, Elizabeth, Gao, Qiong, Che, Harvey, Poon, Evon, Jamin, Yann, Martins Da Costa, Barbara, Barker, Karen, Shrestha, Sumana, Hutchinson, J. Ciaran, Dhariwal, Simran, Goodman, Angharad, Del Nery, Elaine, Gestraud, Pierre, Bhalshankar, Jaydutt, Iddir, Yasmine, Saberi-Ansari, Elnaz, Saint-Charles, Alexandra, Geoerger, Birgit, Marques Da Costa, Maria Eugénia, Pierre-Eugène, Cécile, Janoueix-Lerosey, Isabelle, Decaudin, Didier, Nemati, Fariba, Carcaboso, Angel M., Surdez, Didier, Delattre, Olivier, George, Sally L., Chesler, Louis, Tweddle, Deborah A., Schleiermacher, Gudrun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068437/
https://www.ncbi.nlm.nih.gov/pubmed/36602782
http://dx.doi.org/10.1158/1078-0432.CCR-22-2274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068437/
https://www.ncbi.nlm.nih.gov/pubmed/36602782
http://dx.doi.org/10.1158/1078-0432.CCR-22-2274

Ejemplares similares